BENLYSTA (Human Genome Sciences, Inc.)
Welcome to the PulseAid listing for the BENLYSTA drug offered from Human Genome Sciences, Inc.. This Decreased B Lymphocyte Activation [PE],B Lymphocyte Stimulator-specific Inhibitor [EPC],B Lymphocyte Stimulator-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Human Genome Sciences, Inc. |
| NON-PROPRIETARY NAME: | belimumab |
| SUBSTANCE NAME: | BELIMUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Decreased B Lymphocyte Activation [PE],B Lymphocyte Stimulator-specific Inhibitor [EPC],B Lymphocyte Stimulator-directed Antibody Interactions [MoA] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2017-07-20 |
| END MARKETING DATE: | 0000-00-00 |
BENLYSTA HUMAN PRESCRIPTION DRUG Details:
| Item Description | BENLYSTA from Human Genome Sciences, Inc. |
| LABELER NAME: | Human Genome Sciences, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 200(mg/mL) |
| START MARKETING DATE: | 2017-07-20 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 49401-088_bdb3042f-a604-455a-bbd3-d263a9130c75 |
| PRODUCT NDC: | 49401-088 |
| APPLICATION NUMBER: | BLA761043 |
Other BELIMUMAB Pharmaceutical Manufacturers / Labelers:
